Adverse event (AE) management in patients (pts) with relapsed and refractory multiple myeloma (RRMM) taking pomalidomide (POM) plus low dose-dexamethasone (LoDEX): A pooled analysis from 3 clinical trials.

Philippe Moreau,Meletios A. Dimopoulos,Paul G. Richardson,David Siegel,Antonio Palumbo,Michele Cavo,Paolo Corradini,Katja Weisel,Michel Delforge,Peter O'Gorman,Kevin W. Song,Lars Sternas,Teresa Peluso,Kevin Hong,Jennifer Herring,Xin Yu,Mohamed H. Zaki,Jesús F. San Miguel

Adverse event (AE) management in patients (pts) with relapsed and refractory multiple myeloma (RRMM) taking pomalidomide (POM) plus low dose-dexamethasone (LoDEX): A pooled analysis from 3 clinical trials.

2016

Philippe Moreau
Meletios A. Dimopoulos
Paul G. Richardson
David Siegel
Antonio Palumbo
Michele Cavo
Paolo Corradini
Katja Weisel
Michel Delforge
Peter O'Gorman
Kevin W. Song
Lars Sternas
Teresa Peluso
Kevin Hong
Jennifer Herring
Xin Yu
Mohamed H. Zaki
Jesús F. San Miguel

8031Background: Pts with RRMM who are heavily pretreated often have advanced disease and comorbidities, increasing their susceptibility to AEs. The management of AEs is important to ensure that pts...

Keywords:

Refractory Multiple Myeloma
Dexamethasone
Pomalidomide
Clinical trial
Oncology
Pathology
Adverse effect
Medicine
Internal medicine
pooled analysis
low dose
Physical therapy
in patient

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations